Related Experiment Video
Updated: Jun 1, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Dyslipidemia Impacts Cardiometabolic Health and CVD Risk in a Relatively Young Otherwise Healthy Population
Jillian M Lang1, Elena S Shostak1, William K Quinn1
1Health and Human Physiological Sciences, Skidmore College, Saratoga Springs, New York, USA.
None:
Dyslipidemia, abnormal levels of lipids in the bloodstream, is associated with cardiovascular disease risk (CVD). The purpose of this study was to evaluate the effects of dyslipidemia on cardiometabolic health in relatively young, healthy adults. Participants were 54 healthy males and females aged 18-60 years. Participants were assessed for anthropometrics, body composition, blood pressure and vascular stiffness indicators, microvascular health, and glucose and lipid levels. Using a cross-sectional approach, participants were characterized and grouped as having dyslipidemia or not, and then statistically assessed to determine whether differences in other cardiometabolic health measures existed between the groups. There were significant differences between groups for body weight and composition (total mass, muscle mass, visceral fat, bone mass, and body mass index, all, p < 0.027, Cohen's d > 0.605) with the dyslipidemia group being higher. There were significant differences between groups for peripheral and central blood pressures (all, p < 0.003, Cohen's d > 0.899), as well as for vascular stiffness indicators (pulse pressure, augmentation pressure, augmentation index, augmentation index 75) (all, p < 0.022, Cohen's d > 0.672) with elevations noted in the dyslipidemia group. Ten-year CVD risk was significantly different between groups, with an average risk of 0.8% in the normal lipids group and a risk of 5.4% in the dyslipidemia group (p < 0.001, Cohen's d = 1.260). However, there were no significant differences in macro- or micronutrient intake between groups (all, p > 0.166, Cohen's d < 0.412). There is a significant impact on cardiometabolic health in individuals with dyslipidemia who are otherwise healthy, which may increase individual risk for CVD. Trial Registration: ClinicalTrials.gov identifier: NCT06544915.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...